Supplier log in
Gabapentin and/or Pregabalin RFP
Details
|
Tender Closed
|
|
| RFx ID : | 18654887 |
| Tender Name : | Gabapentin and/or Pregabalin RFP |
| Reference # : | A1011417 |
| Open Date : | Friday, 12 May 2017 3:00 PM (Pacific/Auckland UTC+12:00) |
| Close Date : | Monday, 17 July 2017 5:00 PM (Pacific/Auckland UTC+12:00) |
| Tender Type : | Request for Proposals (RFP) |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Exemption Reason : | None |
| Required Pre-qualifications : | None |
| Contact : |
Chloe Dimock procurement@pharmac.govt.nz |
| Alternate Physical Delivery Address : | |
| Alternate Physical Fax Number : | |
| Agency Address : | |
PHARMAC invites proposals for the supply of oral gabapentin and/or pregabalin in New Zealand.
This request for proposals (RFP) letter incorporates the following schedules:
- Schedule 1 specifies the pharmaceutical for which PHARMAC is requesting proposals and sets out the background to the RFP and the types of proposals sought;
- Schedule 2 describes the process that PHARMAC expects to follow in relation to the RFP;
- Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
- Schedule 4 contains the RFP form in which you are to provide details of your proposal.
If you wish to submit a proposal, you must submit it to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 5.00 p.m. on 6 July 2017.
If you have any questions about this RFP, please post these on GETS or alternatively contact Chloe Dimock by email at procurement@pharmac.govt.nz at PHARMAC.
We look forward to receiving your proposal.
This tender has been awarded to:
- Apotex NZ Ltd
- Pfizer New Zealand Ltd
Further Award Information:
We’re pleased to announce the approval of two agreements, one with Apotex New Zealand Ltd for supply of gabapentin and the other with Pfizer New Zealand Ltd for supply of pregabalin. These agreements were the subject of a consultation letter dated 20 October 2017. In summary, the effect of the decision is that:
From 1 May 2018 Pfizer New Zealand Ltd’s brand of pregabalin (Pregabalin Pfizer) will be funded, via a sole supply arrangement in both the community and hospital settings, without a Special Authority restriction applying.
From 1 June 2018 Apo-Gabapentin (supplied by Apotex New Zealand Ltd) will be funded, via a sole supply arrangement in both the community and hospital settings, without a Special Authority restriction.
From 1 August 2018 Arrow-Gabapentin, Neurontin, and Nupentin will be referenced priced to the cost of Apo-Gabapentin and from 1 November 2018 Arrow-Gabapentin, Neurontin, and Nupentin will be delisted. People using Arrow-Gabapentin, Neurontin, and Nupentin brands of gabapentin will need to switch brands to Apo-Gabapentin to remain on a fully funded product.
A funding condition will be applied to both gabapentin and pregabalin which will prevent funded concurrent use of those products.
Award Date: Friday, 8 December 2017 (Pacific/Auckland UTC+13:00)
Date RFx was completed/updated: Monday, 16 October 2017 5:30 AM (Pacific/Auckland UTC+13:00)
